This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moy, B. Articles by Goss, P. E. Search for Related Content PubMed PubMed Citation Articles by Moy, B. Articles by Goss, P. E.

Breast Cancer

Lapatinib: Current Status and Future Directions in Breast Cancer

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA

Key Words. Lapatinib • GW572016 • Dual tyrosine kinase inhibitor • Breast cancer • EGFR • ErbB-1 • ErbB-2 • HER-2

Correspondence: Paul E. Goss, M.D., Ph.D., Massachusetts General Hospital Cancer Center, Gillette Center for Women’s Cancers, 55 Fruit Street, Lawrence House, LRH 302, Boston, Massachusetts 02114, USA. Telephone: 617-724-3118; Fax: 617-643-0589; e-mail: pgoss{at}partners.org

Lapatinib is an oral receptor tyrosine kinase inhibitor, targeting both the ErbB-1 and ErbB-2 receptors. Pre-clinical in vitro and in vivo models indicate that lapatinib is active as monotherapy, synergistically in combination with trastuzumab, and in trastuzumab-resistant cell lines. Early clinical trials also provide evidence in patients that lapatinib is active against breast cancer. This paper reviews results of phase II and III clinical trials of lapatinib in metastatic breast cancer, evidence for its potential in patients with brain metastases, and current clinical trials as adjuvant treatment in early-stage disease. Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes is allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.

This article has been cited by other articles:

				B. Paul, J. A. Trovato, and J. Thompson Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1703 - 1710. [Abstract] [Full Text] [PDF]

				A. M. Storniolo, M. D. Pegram, B. Overmoyer, P. Silverman, N. W. Peacock, S. F. Jones, J. Loftiss, N. Arya, K. M. Koch, E. Paul, et al. Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3317 - 3323. [Abstract] [Full Text] [PDF]

				J. W. Polli, J. E. Humphreys, K. A. Harmon, S. Castellino, M. J. O'Mara, K. L. Olson, L. St. John-Williams, K. M. Koch, and C. J. Serabjit-Singh The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions Drug Metab. Dispos., April 1, 2008; 36(4): 695 - 701. [Abstract] [Full Text] [PDF]

				C. Widakowich, G. de Castro Jr., E. de Azambuja, P. Dinh, and A. Awada Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers Oncologist, December 1, 2007; 12(12): 1443 - 1455. [Abstract] [Full Text] [PDF]

				B. Moy and P. E. Goss Lapatinib-Associated Toxicity and Practical Management Recommendations Oncologist, July 1, 2007; 12(7): 756 - 765. [Abstract] [Full Text] [PDF]